Commentary on "Effects of Once-weekly Dulaglutide on Juvenile Type 2 Diabetes Mellitus and Obesity in Korea: a Pilot Study"

Overview

Journal Ann Pediatr Endocrinol Metab

Specialty Pediatrics

Date 2024 Jan 4

PMID 38173379

Authors

Han Hyuk Lim

Affiliations

Soon will be listed here.

References

Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

Shah A, Zeitler P, Wong J, Pena A, Wicklow B, Arslanian S . ISPAD Clinical Practice Consensus Guidelines 2022: Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022; 23(7):872-902. DOI: 10.1111/pedi.13409. View

Garvick S, Altenburg L, Dunlap B, Fisher A, Watson A, Gregory T . Diagnosis and management of type 2 diabetes in children. JAAPA. 2022; 35(7):16-22. DOI: 10.1097/01.JAA.0000832648.15129.b8. View

Ha J, Oh Y, Kang E, Nam H, Rhie Y, Lee K . Single Point Insulin Sensitivity Estimator for predicting type 2 diabetes mellitus in obese adolescents. Ann Pediatr Endocrinol Metab. 2022; 27(3):201-206. PMC: 9537672. DOI: 10.6065/apem.2142178.089. View

Tamborlane W, Laffel L, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J . Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022; 10(5):341-350. PMC: 10851108. DOI: 10.1016/S2213-8587(22)00052-3. View

Berman C, Vidmar A, Chao L . Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. touchREV Endocrinol. 2023; 19(1):38-45. PMC: 10258616. DOI: 10.17925/EE.2023.19.1.38. View

Michaliszyn S, Mari A, Lee S, Bacha F, Tfayli H, Farchoukh L . β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014; 63(11):3846-55. PMC: 4207396. DOI: 10.2337/db13-1951. View

Kim J, Lee J . Role of obesity-induced inflammation in the development of insulin resistance and type 2 diabetes: history of the research and remaining questions. Ann Pediatr Endocrinol Metab. 2021; 26(1):1-13. PMC: 8026341. DOI: 10.6065/apem.2040188.094. View

Tamborlane W, Shehadeh N . Unmet Needs in the Treatment of Childhood Type 2 Diabetes: A Narrative Review. Adv Ther. 2023; 40(11):4711-4720. PMC: 10567925. DOI: 10.1007/s12325-023-02642-7. View

10.

Constantino M, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T . Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013; 36(12):3863-9. PMC: 3836093. DOI: 10.2337/dc12-2455. View

11.

Seo J, Lee C, Choi H, Lee H, Lee S, Kim H . Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study. Ann Pediatr Endocrinol Metab. 2023; 28(4):296-301. PMC: 10765027. DOI: 10.6065/apem.2244196.098. View

12.

Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B . Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021; 385(5):416-426. PMC: 8697255. DOI: 10.1056/NEJMoa2100165. View